Literature DB >> 10657568

Metabolism of apolipoproteins AI and AII in subjects carrying similar apoAI mutations, apoAI Milano and apoAI Paris.

O Perez-Mendez1, E Bruckert, G Franceschini, N Duhal, B Lacroix, J P Bonte, C Sirtori, J C Fruchart, G Turpin, G Luc.   

Abstract

ApoAI Milano (AI(M)) and apoAI Paris (AI(P)) are mutant forms of apoAI in which cysteine is substituted for arginine at residues 173 and 151 respectively leading to the formation of homodimers and heterodimers with apoAII. Heterozygous subjects with these mutants are characterized by low levels of plasma HDL cholesterol and apoAI. The present study analyzed the metabolism of the different complexes of apoAI in three subjects, two AI(M) and one AI(P), using a primed-constant infusion of trideuterated leucine. In AI(M) carriers, the mutant form was almost equally distributed in AI(M) dimer, AI(M):AII heterodimer and the monomer, whereas, in the AI(P) subject, the mutant apoAI was essentially in the apoAI(P):AII complex. Normal apoAI was low in the AI(M) subjects (20 and 16 mg/dl) but very low in the AI(P) subject (0.3 mg/dl). In the AI(M) subjects, the low levels of apoAI were due to a rapid catabolism with a normal synthetic rate. However, the apoAI kinetics were heterogeneous with a rapid catabolism of the AI(M):AII complex (FCR of 0.430 and 0.401 day(-1)) and the AI(M) monomer (FCR of 0.570 and 0.406 day(-1)) whereas the AI(M) dimer was catabolized slowly (FCR of 0.114 and 0. 118 day(-1)). In contrast, AI(P) was catabolized relatively slowly with a FCR of 0.263, 0.182 and 0.258 day(-1) for AI(P) homodimer, apoAI(P):AII heterodimer and AI(P) monomer. In the three subjects, normal apoAI was catabolized quickly, with an FCR of 0.805 and 0.601 day(-1) in AI(M) carriers and 0.526 day(-1) in the AI(P) carrier. Therefore, the low level of apoAI in the AI(P) carrier is caused by a low production rate of apoAI, particularly of normal apoAI. In conclusion, apoAI is kinetically heterogeneous in AI(M) and in AI(P) subjects. Moreover, the two mutations lead to significant differences in the kinetic behavior of mutant apoAI depending on its inclusion in its complexes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10657568     DOI: 10.1016/s0021-9150(99)00279-8

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  11 in total

Review 1.  Studying apolipoprotein turnover with stable isotope tracers: correct analysis is by modeling enrichments.

Authors:  Rajasekhar Ramakrishnan
Journal:  J Lipid Res       Date:  2006-09-01       Impact factor: 5.922

2.  Surface rheology and adsorption kinetics reveal the relative amphiphilicity, interfacial activity, and stability of human exchangeable apolipoproteins.

Authors:  Victor Martin Bolanos-Garcia; Anne Renault; Sylvie Beaufils
Journal:  Biophys J       Date:  2007-11-09       Impact factor: 4.033

3.  Tweaking the cholesterol efflux capacity of reconstituted HDL.

Authors:  Cheng-I J Ma; Jennifer A Beckstead; Airlia Thompson; Anouar Hafiane; Rui Hao Leo Wang; Robert O Ryan; Robert S Kiss
Journal:  Biochem Cell Biol       Date:  2012-05-18       Impact factor: 3.626

4.  Crystal structure of C-terminal truncated apolipoprotein A-I reveals the assembly of high density lipoprotein (HDL) by dimerization.

Authors:  Xiaohu Mei; David Atkinson
Journal:  J Biol Chem       Date:  2011-09-13       Impact factor: 5.157

Review 5.  Will torcetrapib be the next big thing in coronary heart disease risk reduction?

Authors:  James M McKenney; John A Hoekstra
Journal:  Curr Atheroscler Rep       Date:  2007-01       Impact factor: 5.113

6.  Structural and functional consequences of the Milano mutation (R173C) in human apolipoprotein A-I.

Authors:  Eric T Alexander; Masafumi Tanaka; Momoe Kono; Hiroyuki Saito; Daniel J Rader; Michael C Phillips
Journal:  J Lipid Res       Date:  2009-03-24       Impact factor: 5.922

Review 7.  Structural basis for distinct functions of the naturally occurring Cys mutants of human apolipoprotein A-I.

Authors:  Olga Gursky; Martin K Jones; Xiaohu Mei; Jere P Segrest; David Atkinson
Journal:  J Lipid Res       Date:  2013-09-13       Impact factor: 5.922

Review 8.  ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future.

Authors:  Arzu Kalayci; C Michael Gibson; Paul M Ridker; Samuel D Wright; Bronwyn A Kingwell; Serge Korjian; Gerald Chi; Jane J Lee; Pierluigi Tricoci; S Hassan Kazmi; Clara Fitzgerald; Alka Shaunik; Gail Berman; Danielle Duffy; Peter Libby
Journal:  Curr Atheroscler Rep       Date:  2022-05-07       Impact factor: 5.967

Review 9.  Will Lipidation of ApoA1 through Interaction with ABCA1 at the Intestinal Level Affect the Protective Functions of HDL?

Authors:  Eric J Niesor
Journal:  Biology (Basel)       Date:  2015-01-06

Review 10.  Excess coronary artery disease risk in South Asian immigrants: can dysfunctional high-density lipoprotein explain increased risk?

Authors:  Sunita Dodani
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.